Clinical Trial Update: Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of lurbinectedin as monotherapy in participants with advanced or metastatic solid tumors was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homologous Recombination Deficiency-positive Malignancies
• Poorly Differentiated Neuroendocrine Carcinomas
• Urothelial Cancer

Drugs mentioned

• Zepzelca (lurbinectedin) (Lurbinectedin)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2025-02-28